Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis
Published in Lancet Rheumatol, 2022
DOI: 10.1016/S2665-9913(22)00095-9PMID: 38294031
Recommended citation: van Wesemael TJ, Verstappen M, Knevel R, van der Helm-van Mil AHM, Toes REM, van der Woude D. (2022) "Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis" Lancet Rheumatol. 2022 May;4(5):e316-e317. doi: 10.1016/S2665-9913(22)00095-9.
Recommended citation: van Wesemael TJ, Verstappen M, Knevel R, van der Helm-van Mil AHM, Toes REM, van der Woude D. (2022) "Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis" Lancet Rheumatol. 2022 May;4(5):e316-e317. doi: 10.1016/S2665-9913(22)00095-9.
Download Paper